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Abstract
In recognition of the benefits of transparent reporting, many peer-reviewed journals require that their authors be
prepared to share their raw, unprocessed data with other scientists and/or state the availability of raw data in pub-
lished articles. But little information on how data should be prepared for publication - or sharing - has emerged. In
clinical research patient privacy and consent for use of personal health information are key considerations, but
agreed-upon definitions of what constitutes anonymised patient information do not appear to have been estab-
lished. We aim to address this issue by providing practical guidance for those involved in the publication process,
by proposing a minimum standard for de-identifying datasets for the purposes of publication in a peer-reviewed
biomedical journal, or sharing with other researchers. Basic advice on file preparation is provided along with proce-
dural guidance on prospective and retrospective publication of raw data, with an emphasis on randomised con-
trolled trials.
In order to encourage its wide dissemination this article is freely accessible on the BMJ and Trials journal web sites.
Background
Many peer-reviewed journals’ instructions for authors
require that authors should be prepared to share their
raw (that is, unprocessed) data with other scientists on
request. Although data sharing is commonplace in some
scientific disciplines and is a requirement of a number
of major research funding agencies’ policies, this culture
has not yet been widely adopted by the clinical research
community. Some journals have appealed to their
authors to increase the availability of medical research
data [1-3], recognising the benefits of such transparency.
These benefits are well documented and include replica-
tion of previous findings, comparisons with independent
datasets, testing of additional hypotheses, teaching, and
patient safety [3-6]. Moreover, patients themselves are
increasingly seeing the benefits of openly sharing their
experiences with others [7].
Online journals with unlimited space now provide the
platform for publishing large, raw datasets as supple-
mentary material [5,8], but a common concern is confi-
dentiality. If there is any doubt over anonymity,
publishing data that have arisen from the doctor-patient
or researcher-participant relationship will raise issues of
privacy unless explicit and properly informed consent to
all of the intended uses of that data has been obtained.
The International Committee of Medical Journal Edi-
tors’ Uniform Requirements for Manuscripts Submitted
to Biomedical Journals require that patient privacy be
protected, and maintaining confidentiality and privacy is
ingrained in various legal statutes such as the UK Data
Protection Act and the Health Insurance Portability and
Accountability Act (HIPAA) in the US [9].
In Europe, the Data Protection Directive (Directive 95/
46/EC) provides some harmony in data protection legis-
lation, but in the US there is no overarching data pro-
tection law. Therefore, in an increasingly global research
and publishing industry, universally agreed definitions as
to what constitutes anonymised patient information
would benefit clinical researchers. The HIPAA provides
a list of 18 items that need to be removed from patient
information in order for it to be considered anonymous
for the purposes of sharing information between the
“covered entities” specified in the act, but the list was
not designed with publication in biomedical journals in
mind. A number of publications from UK bodies
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tion [10-13], but none is as explicit as the HIPAA.
This article aims to provide practical guidance for
those involved in the publication process by proposing a
minimum standard for anonymising (or de-identifying)
data for the purposes of publication in a peer-reviewed
biomedical journal or sharing with other researchers,
either directly, where appropriate, or via a third party.
Basic advice on file preparation is also provided, along
with procedural guidance on prospective and retrospec-
tive publication of raw clinical data. Although the focus
of this discussion is on data from randomised trials, the
same issues of confidentiality apply to data from any
research study involving human subjects, including
cohort, case-control, and case series designs.
Data preparation guidance
What is the dataset?
For the purposes of this guidance, the dataset is the
aggregated collection of patient observations (including
sociodemographic and clinical information) used for the
purposes of producing the summary statistical findings
presented in the main report of the research project,
whether previously published or not.
Data are almost always collected at a greater level of
detail than are reported in a journal article. For example,
each participant in a pain study may complete a pain
diary twice a day for 30 days, with the authors reporting
“mean post-treatment pain” for one or more groups of
participants. Similarly, a quality of life questionnaire
may include a large number of questions divided into
domains such as physical, mental, emotional, and social
wellbeing.
Here we define a dataset as that containing the mini-
mum level of detail necessary to reproduce all numbers
reported in the paper. The dataset for the pain trial, for
example, might therefore consist of one value per indivi-
dual for mean post-treatment pain rather than 30 values
for pain levels on each day. However, if more detailed,
underlying data are available and can be shared then
that should also be encouraged, provided the data con-
form to the same standards–as proposed in this article–
as the main dataset. If possible, authors should present
all outcomes and variables, regardless of significance.
Anonymisation
A list of 28 patient identifiers has been formulated,
based on information aggregated from policy documents
and research guidance from major UK and US funding
agencies, governmental health departments and statutes,
and three internationally recognised publication ethics
resources for editors of biomedical journals [9-16]. This
list is provided in Table 1.
Types of identifying information have been classified
as either direct or indirect. Publication of any direct
identifiers places individuals in the dataset at risk of
being identified. Although none of the indirect identi-
fiers on its own would point to an individual, a dataset
with several indirect identifiers, especially those relating
to attributes, might do. The consensus of the authors,
and working group members acknowledged in the cur-
rent manuscript, is that a dataset including three or
more indirect identifiers should be assessed by an inde-
pendent researcher or ethics committee to evaluate the
risk that individuals might be identifiable. If the risk of
identification is considered non-negligible, before publi-
cation can proceed approval should be sought from a
relevant advisory body (see below). An explicit justifica-
tion for publication of a dataset with three or more
indirect identifiers should be given by the researcher–as
an annotation to the dataset and in any accompanying
articles. This should include the name of any oversight
bodies consulted.
Use of dates relevant to individuals
In circumstances where it is essential for the scientific
validity of the study to include dates, such as dates of
treatment (a direct identifier), data must be presented in
such a way that is unlikely to affect statistical analyses
but preserves anonymity. For example, one could add or
subtract a small, randomly chosen number of days to all
dates, so that the true dates are not published. In cases
where it is necessary to include dates, this fact and any
supporting information should be disclosed on submis-
sion to the journal.
File preparation
Authors should provide a clean, well annotated dataset
in a suitable format so that statistical analyses could be
conducted. By “clean,” we mean reviewed systematically
for duplicates, errors, and missing data; by “well anno-
tated,” we mean that sufficient information is given
about each variable to allow replication of the originally
published results. For example, the dataset included as
supplementary material by Vickers [5] includes a brief
description of the study and data and a detailed explana-
tion of each variable on the dataset. It is recommended
that file formats be as general as possible. Microsoft
Excel is widely used and delimited text format is univer-
sally convertible, so these formats are preferable to files
saved in formats specific to statistical software such as
SAS or STATA. If a dataset may be updated in the
future–for example, in cancer studies where follow-up is
continued over many years–it could be given a version
number or date.
Copyright
Where datasets are being published as supplementary
material in a journal that requires transfer of copyright
to the publisher, it is recommended the supporting data
be separated from the article itself and that transfer of
copyright for the data is not required as a condition of
publication. Of note, there is no protection by
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research purposes [17]–f a c t st h e m s e l v e sa r en o tc o p y -
rightable, only the way in which they are expressed.
Prospective data publication
W i t ht h ei n c r e a s i n gp r e v a l e n c eo fd a t as h a r i n gp o l i c i e s
from research funding agencies, researchers should be
encouraged to make allowances for data sharing or pub-
lication when preparing study protocols. Although con-
sent is not required in law to process anonymised data,
ideally informed consent should be obtained from
research participants for the publication of suitably
anonymised raw data, as part of the recruitment process,
for all new studies. Researchers should inform partici-
pants of all possibilities for the use of their information
and allow them to choose. Participants who do not
agree to publication of potentially identifying informa-
tion may need to be removed from the dataset [16].
Approval or consent should include use of the data in
subsequent meta-analyses. Research ethics committees
should also encourage researchers to include details of
the intention to publish data in the study information
sheets that are provided to study participants, and to
ensure that safeguards are in place to protect patient
privacy. In the absence of mandates for data sharing or
publication, research funding agencies should give
greater scrutiny to data sharing plans referred to in their
policy documents and check their enforcement.
Retrospective data publication
There will be instances when researchers wish to pub-
lish a dataset retrospectively. This might be from cur-
rent clinical research that was conducted without
explicit consent for data sharing or publication from the
participants (due to a lack of specific requirements of
funders or regulators) or use of data from a historic
piece of research conducted before data sharing policies
were established.
Table 1 Aggregated list of potential patient identifiers in datasets
Identifier (information sources) Comments
Direct
Name [9-16]
Initials [14]
Address, including full or partial postal code [9-16]
Telephone or fax numbers or contact information [9,11,13,16]
Electronic mail addresses [9]
Unique identifying numbers [9-16] Generalised HIPPA item 7-10, 18
Vehicle identifiers [9]
Medical device identifiers [9]
Web or internet protocol addresses [9]
Biometric data [9]
Facial photograph or comparable image [9,11,12,14]
Audiotapes [12]
Names of relatives [11]
Dates related to an individual (including date of birth) [9,10,12,16]
Indirect–may present a risk if present in combination with others in the list
Place of treatment or health professional responsible for care [11,16] Could be inferred from investigator affiliations
Sex [10]
Rare disease or treatment [11]
Sensitive data, such as illicit drug use or “risky behaviour” [16]
Place of birth [11,16]
Socioeconomic data, such as occupation or place of work, income, or education
[10,11,13,16]
MRC requirement is for “rare” occupations only
Household and family composition [16]
Anthropometry measures [16]
Multiple pregnancies [16]
Ethnicity [10]
Small denominators–population size of <100 [15]
Very small numerators–event counts of <3 [15]
Year of birth or age (this article) Age is potentially identifying if the recruitment period is short and
is fully described
Verbatim responses or transcripts [16]
Hrynaszkiewicz et al. Trials 2010, 11:9
http://www.trialsjournal.com/content/11/1/9
Page 3 of 5In such cases, researchers may publish raw data if it is
clear and demonstrable that there is no threat to anon-
ymity–for example, if the dataset includes no direct
identifiers and fewer than three indirect identifiers. If it
is not certain that data are completely anonymous, and
where consent of all participants is not possible, a care-
ful case-by-case assessment must be made–taking into
account public interest and scientific imperative for
publication–before publishing the data. Where there is a
risk of identification, we recommend authors consult
local ethics committees about their wish to publish their
raw data in a freely accessible manner before submitting
it for publication. When the relevant committee no
longer exists, the authors are encouraged to consult an
appropriate national advisory body. In the UK, for
example, the National Information Governance Board
for Health and Social Care (NIGB), formerly the Patient
Information Advisory Group, provides advice on issues
of national significance involving the use of patient
information. The NIGB includes the Ethics and Confi-
dentiality Committee. Such bodies may not be in a posi-
tion to approve the decision to publish raw data, but
they could provide a valuable opinion. Advice may also
be sought from the Caldicott Guardian (a person
responsible for protecting patient confidentiality) or
equivalent person within the author’s institution. In the
US, a research ethics consultation could be considered
in addition to institutional review board approval.
A case-by-case judgment, whether this is by an advi-
sory body or the journal editor, will need to take into
account the sample size, the ways in which results will
be published and used, and all other circumstances of
the study. For example, the fact that research findings
are increasingly being published in open access journals,
so that a published dataset would be visible to anyone
with an internet connection, arguably makes any issues
of confidentiality and anonymity even more important.
Preparing for journal submission–statement in submitted
manuscript
Authors should be asked to state in their manuscript if
informed consent for data publication has been
obtained. If consent was not obtained, authors should
be asked to state the reasons for this and the name of
the body that gave approval or any guidance adhered to
in preparing their data for publication. In practice,
authors could make one of three statements:
1 Consent for publication of raw data obtained from
study participants
2 Consent for publication of raw data not obtained
but dataset is fully anonymous in a manner that can
easily be verified by any user of the dataset. Publication
of the dataset clearly and obviously presents minimal
risk to confidentiality of study participants
3 Consent for publication of raw data not obtained
and dataset could in theory pose a threat to
confidentiality.
For statements 2 and 3, authors should also provide:
￿ Reasons why it was not possible to obtain consent
￿ Reasons why publication of data constituted a negli-
gible risk to confidentiality or reasons why benefit of
publishing data outweighs a non-negligible risk to confi-
dentiality, plus the name of an oversight body consulted
for approval of publication or guidance.
Alternatives to journal publication
There will be circumstances where raw data cannot be
published in journals, because of policy or space restric-
tions, but alternatives do exist. These include online
repositories and databases such as the Dataverse Net-
work Project [18]. Specialist data centres or archives are
also emerging, such as the UK Data Archive [19]. But in
all cases, whether data are published or deposited,
restrictions on access to certain aspects of data may be
warranted, such as when removal of information that
could identify the data would negate its scientific value.
In circumstances where data must be behind a barrier
to universal access, the data could be made accessible
only to those who agree to certain conditions of use,
and to individuals who meet certain professional criteria.
Embargoes on access to data could also be applied [3].
Limitations of this guidance
This guidance is directed at quantitative research data
and should be applicable to most observational studies
and randomised controlled trials. Qualitative or mixed
methods researchers should seek alternative advice. The
UK Data Archive, for example, has produced guidance
on anonymisation techniques for qualitative data [20].
An important limitation of the search strategy used in
preparing Table 1 is that it is restricted to US HIPAA
guidance and known UK bodies with an interest in
maintaining confidentiality in human subjects research.
Investigation of requirements of non-English speaking
nations would be beneficial. This guidance is aimed at
those producing data: guidelines for use of published
data have been reported separately [5].
Some advocates of clinical data sharing are also keen
for data to be shared in agreed, standardised formats to
facilitate its automated re-use for statistical analysis [21].
Although basic principles of data preparation have been
provided, how this relates to initiatives aimed at stan-
dardising raw data are beyond the scope of this
document.
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